New breast cancer drug tested against standard treatment in phase 3 trial
NCT ID NCT06884254
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 24 times
Summary
This study compares a new drug called EG1206A to the approved drug Perjeta, both given with trastuzumab and chemotherapy, for people with HER2-positive early breast cancer. The treatment is given before and after surgery to see if the new drug works as well as the standard one. The study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Methodist Health System Clinical Research Institute
Dallas, Texas, 75023, United States
Conditions
Explore the condition pages connected to this study.